Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Jessup Website

John M. Jessup, M.D.

Portait Photo of John Jessup
Laboratory of Experimental Carcinogenesis
Adjunct Investigator
Center for Cancer Research
National Cancer Institute
Executive Plaza North (EPN), Room 6040
6130 Executive Blvd.
Rockville, MD 20892-7420
Phone:  
301-435-9010
Fax:  
301-402-7819
E-Mail:  
jessupj@mail.nih.gov

Biography

J. Milburn Jessup, MD is a surgical oncologist and scientist who has joined the Laboratory of Experimental Carcinogenesis as an Adjunct Investigator in CCR. He is also Chief of the Diagnostics Evaluation Branch of the Cancer Diagnosis Program in DCTD. In 25 years of practice he focused on the multidisciplinary treatment of GI and breast cancer, melanoma and soft tissue/skeletal sarcomas in several different academic settings. He has led a research effort to study the mechanisms by which human colorectal carcinomas form hepatic metastasis and identified roles for the marker Carcinoembryonic Antigen in modulating inflammatory responses and promoting metastasis. He is currently Chair of the AJCC Hindgut Task Force that formulates the TNM staging classification in the US. He has been involved for over a decade with the American College of Surgeons Commission on Cancer and served as Chair of the National Cancer Data Committee that oversees hospital tumor registries throughout the US. Dr. Jessup also aids investigators in facilitating the development of biomarkers for clinical use in patients with cancer.

Research

The focus of Dr. Jessup's research effort currently is on cancer stem cells (CSC) in colorectal carcinoma that give rise to liver metastases. The major interest is in the role of pluripotency transcription factors in regulating quiescence, differentiation and metastasis by putative CSC. An important related scientific interest is in the mechanisms by which metastatic precursor cells survive toxic drugs or host microenvironments and approaches to ablate that resistance.

This page was last updated on 7/10/2013.